Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67? - 01/03/22
Doi : 10.1016/S1470-2045(21)00756-7
Gabriele Antonarelli a, b, Carmine Valenza a, b, Erica L Mayer c, d, Sibylle Loibl e, f, g, Giuseppe Curigliano a, b 
a Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan 20141, Italy
b Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
c Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
d Breast Oncology Center, Harvard Medical School, Boston, MA, USA
e German Breast Group, Neu-Isenburg, Germany
f Center for Hematology and Oncology Bethanien, Frankfurt, Germany
g Department of Medicine and Research, Goethe University of Frankfurt, Frankfurt, Germany
El texto completo de este artículo está disponible en PDF.
© 2022
Elsevier Ltd. Reservados todos los derechos.
Vol 23 - N° 3
P. 325-328 - mars 2022 Regresar al número
Artículo precedente
- Importing oncology trials from China: a bridge over troubled waters?
- Harpreet Singh, Richard Pazdur
- Progression-free survival: it is time for a new name
- Bishal Gyawali, Elizabeth Eisenhauer, Michelle Tregear, Christopher M Booth
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?